Institution statistics

GENETHON - France 

Ranking results:

Past rankings:
2019
Criterium:Position:
Overall Score:> 1000
Total Project Funding per Partner:> 1000
Total Number of Projects:> 1000
2018
Criterium:Position:
Overall Score:500-600
Total Project Funding per Partner:300-400
Total Number of Projects:> 1000
Networking Rank (Reputation):400-500
2016
Criterium:Position:
Overall Score:> 1000
Networking Rank (Reputation):> 1000
2015
Criterium:Position:
Overall Score:> 1000
Networking Rank (Reputation):> 1000
2012
Criterium:Position:
Overall Score:900-1000
Total Project Funding per Partner:> 1000
Total Number of Projects:70
Total Project Funding:> 1000
Networking Rank (Reputation):> 1000
Networking Rank (Reputation):> 1000
Partner Constancy:46
Project Leadership Index:75
Diversity Index:60
2011
Criterium:Position:
Overall Score:> 1000
Total Project Funding per Partner:300-400
Total Number of Projects:> 1000
Total Project Funding:> 1000
Networking Rank (Reputation):> 1000
Partner Constancy:> 1000
Project Leadership Index:> 1000
Diversity Index:> 1000
2009
Criterium:Position:
Overall Score:> 1000
Networking Rank (Reputation):> 1000
2008
Criterium:Position:
Overall Score:> 1000
Total Project Funding per Partner:> 1000
Total Number of Projects:> 1000
Total Project Funding:> 1000
Networking Rank (Reputation):> 1000
Partner Constancy:> 1000
Project Leadership Index:> 1000
Diversity Index:> 1000
2007
Criterium:Position:
Overall Score:> 1000
Total Project Funding per Partner:400-500
Total Number of Projects:900-1000
Total Project Funding:400-500
Networking Rank (Reputation):> 1000
Partner Constancy:> 1000
Project Leadership Index:> 1000
Diversity Index:> 1000
Ranking timeline:

European project participation (2000-01-01 - 2020-12-31 ):

Performance:

Funding:

Total funding allocated to projects this organisation participated or coordinated

Funding per Partner:

Since 2014 individual funding per partner. If data is not available at CORDIS: total funding / No of participants.

Projects:
Leadership:

Total number of projects: 22
As coordinator: 2
As participant: 17
Sole participant: 3
Coordinator / Participant Ratio: 0.12*

*Ratio includes only projects with > 2 partners

Summary:
Total project funding [€]:Projects [No]:
Year:coordinator*participant*per partner  as coordinatoras participant
2019 173.076 0 173.076 1
2018 6.249.104 5.998.516 3.829.548 1 1
2017 185.076 0 185.076 1
2016 173.076 14.383.251 2.540.739 1 3
2015 0 5.980.435 0 1
2013 0 5.380.170 630.919 1
2012 5.999.607 0 545.419 1
2011 0 7.171.654 2.541.158 2
2009 0 11.181.411 385.566 1
2008 0 2.907.735 207.695 1
2007 0 12.499.746 648.120 2
2006 0 16.680.000 841.355 3
2005 0 284.000 31.556 1
2004 0 11.635.000 484.792 1
*n.b.: These numbers represent the total amount of funds allocated to projects this institution has participated in, not the funding allocated to this institution

Networking:

Partners:
Institution:Projects [No]:
INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE9
UNIVERSITY COLLEGE LONDON9
ASSISTANCE PUBLIQUE HOPITAUX DE PARIS6
GENOSAFE SAS6
DEUTSCHES KREBSFORSCHUNGSZENTRUM5
MEDIZINISCHE HOCHSCHULE HANNOVER5
ACIES SAS4
EUROPAEISCHES INSTITUT FUER FORSCHUNG UND ENTWICKLUNG VON TRANSPLANTATIONSSTRATEGIEN4
FONDAZIONE CENTRO SAN RAFFAELE DEL MONTE TABOR4
GATC BIOTECH4
UNIVERSITAETSKLINIKUM FREIBURG4
UNIVERSITAT AUTONOMA DE BARCELONA4
CENTRO DE INVESTIGACIONES ENERGETICAS MEDIOAMBIENTALES Y TECNOLOGICAS3
ECOLE POLYTECHNIQUE FEDERALE DE LAUSANNE3
FONDAZIONE TELETHON3
GEORG SPEYER HAUS CHEMOTHERAPEUTISCHES FORSCHUNGSINSTITUT3
INSERM TRANSFERT3
KAROLINSKA INSTITUTE3
KING'S COLLEGE LONDON3
LEIDEN UNIVERSITY MEDICAL CENTER3
VRIJE UNIVERSITEIT BRUSSEL3
CELLGENIX TECHNOLOGIE TRANSFER2
CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE2
COMMISSARIAT A L'ENERGIE ATOMIQUE2
DEBRA EUROPE2
EURICE EUROPEAN RESEARCH AND PROJECT OFFICE2
IMPERIAL COLLEGE OF SCIENCE TECHNOLOGY AND MEDICINE2
INSTITUTO DE BIOLOGIA EXPERIMENTAL E TECNOLOGICA2
LUDWIG MAXIMILIANS UNIVERSITAET MUENCHEN2
LUNDS UNIVERSITET2
MAX DELBRUECK CENTRUM FUER MOLEKULARE MEDIZIN2
MOLECULAR MEDICINE2
ROYAL HOLLOWAY AND BEDFORD NEW COLLEGE2
UNIVERSITA DEGLI STUDI DI MODENA E REGGIO EMILIA2
UNIVERSITA VITA SALUTE SAN RAFFAELE2
UNIVERSITY OF EASTERN FINLAND2
UNIVERSITY OF NEWCASTLE UPON TYNE2
3H BIOMEDICAL AB1
ACADEMISCH MEDISCH CENTRUM BIJ DE UNIVERSITEIT VAN AMSTERDAM1
ACADEMISCH ZIEKENHUIS LEIDEN1
ALTONABIOTEC1
ARK THERAPEUTICS LIMITED1
ASPHALION SL1
ASSOCIATION FRANCAISE CONTRE LES MYOPATHIES1
ASSOCIATION FRANCAISE DE CRIGLER NAJJAR1
ASSOCIATION INSTITUT DE MYOLOGIE1
AZIENDA OSPEDALIERA PAPA GIOVANNI XXIII1
BIOALLIANCE PHARMA1
BIORELIANCE1
CENTRE HOSPITALIER UNIVERSITAIRE DE NANTES1
CENTRE HOSPITALIER UNIVERSITAIRE VAUDOIS1
CHARITE UNIVERSITAETSMEDIZIN BERLIN1
CHRISTOS PAPADOPOULOS & SIA OE1
CLEAN CELLS1
DLD GESELLSCHAFT FUR DIAGNOSTIKA UND MEDIZINISCHE GERATE MBH1
ECBIO INVESTIGACAO E DESENVOLVIMENTO EM BIOTECNOLOGIA S A1
ECOLE NORMALE SUPERIEURE DE CACHAN1
EIDGENOESSISCHE TECHNISCHE HOCHSCHULE ZUERICH1
ENVIGO CRS LIMITED1
EPIXIS1
ERASMUS UNIVERSITAIR MEDISCH CENTRUM ROTTERDAM1
ERASMUS UNIVERSITY MEDICAL CENTER ROTTERDAM1
EUROPEAN GENETIC ALLIANCES' NETWORK1
EUROPEAN MOLECULAR BIOLOGY LABORATORY1
EUROPEAN NEUROMUSCULAR CENTRE1
EUROPEAN ORGANISATION FOR RARE DISEASES1
FINOVATIS1
FODOR JOZSEF NATIONAL CENTER FOR PUBLIC HEALTH1
FONDAZIONE PER LA RICERCA BIOMEDICA AVANZATA ONLUS1
FOUNDATION OF BIOMEDICAL RESEARCH1
FUNDACION PARA LA INVESTIGACION BIOMEDICA HOSPITAL INFANTIL UNIVERSITARIO NINO JESUS1
GENEWERK1
GENOMINING1
GREAT ORMOND STREET HOSPITAL FOR CHILDREN NHS FOUNDATION TRUST1
HELMHOLTZZENTRUM FUER INFEKTIONSFORSCHUNG1
HET ROTTERDAMS OOGHEELKUNDIG INSTITUUT BV1
IMMUNDIAGNOSTIK1
INNOVACION DESARROLLO Y TRANSFERENCIA DE TECNOLOGIA1
INSTITUT CATALA DE LA SALUT1
INSTITUTO INVESTIGACION SANITARIA FUNDACION JIMENEZ DIAZ1
INTERNATIONAL CENTRE FOR GENETIC ENGINEERING AND BIOTECHNOLOGY1
INTERNATIONAL PATIENT ORGANISATION FOR PRIMARY IMMUNODEFICIENCIES1
JULIUSMAXIMILIANS UNIVERSITAET WUERZBURG1
JUSTUS LIEBIG UNIVERSITAET GIESSEN1
KLINIKUM DER JOHANN WOLFGANG GOETHE UNIVERSITAET1
KNIGHT SCIENTIFIC LIMITED1
LOUISE VAN DEN BOS SCIENCE & TECHNOLOGY TRANSFER1
MAX PLANCK GESELLSCHAFT ZUR FOERDERUNG DER WISSENSCHAFTEN E V1
MAYO CLINIC ROCHESTER1
MC TOXICOLOGY CONSULTING1
MEDICAL RESEARCH COUNCIL1
MEDIZINISCHE UNIVERSITAET INNSBRUCK1
MILTENYI BIOTEC1
MUSKELDYSTROPHIE NETZWERK E V1
MYOMEDIX1
NATIONAL AND KAPODISTRIAN UNIVERSITY OF ATHENS1
NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH1
NOVAMEN1
NOVAMEN SAS1
NOVARTIS PHARMA1
Constancy:

Total number of partners:249

Partner loyalty:
Frequent Partner: (> 2 projects): 91
Rare Partner: 158

Frequent / Rare Partner Ratio: 0.58

Diversity:

Categories:
Category:No:
BIOLOGICAL SCIENCES11
RTD HORIZONTAL TOPICS4
SOCIAL AND ECONOMIC CONCERNS1

Project overview:

Start dateProjectacronymrolefundingpartners
2019-01-01Targeting mitochondrial defects and oxidative stress in Pompe Disease: from pathogenesis to therapy MITOPOMPEcoordinator173.0761
2018-01-01Clinical trial of gene therapy with dual AAV vectors for retinitis pigmentosa in patients with Usher syndrome type IB UshTherparticipant5.998.5169
2018-01-01Adeno-Associated Virus Vector-Mediated Liver Gene Therapy for Crigler-Najjar Syndrome CureCNcoordinator6.249.10411
2017-03-01Correction of duplications in the DMD gene by a CRISPR/Cas9 approach DMD2CUREcoordinator185.0761
2016-03-01Muscle Stress Relief: An integrated research program linking together basic research on secondary myopathies in stress states to innovative translation in applied myology. Muscle stress reliefparticipant1.458.00021
2016-01-01DevelopIng Genetic medicines for Severe Combined Immunodeficiency (SCID) SCIDNETparticipant6.926.31312
2016-01-01Genetic correction of glycogen debranching enzyme deficiency in Glycogen Storage disease III: a proof of concept study GLYCODIS3coordinator173.0761
2016-01-01Development of an innovative gene therapy platform to cure rare hereditary muscle disorders MYOCUREparticipant5.998.9389
2015-09-01Efficacy and safety of low-dose IL-2 (ld-IL-2) as a Treg enhancer for anti-neuroinflammatory therapy in newly diagnosed Amyotrophic Lateral Sclerosis (ALS) patients MIROCALSparticipant5.980.43512
2013-01-01Phase I/II Gene Therapy Trial of Fanconi anemia patients with a new Orphan Drug consisting of a lentiviral vector carrying the FANCA gene: A Coordinated International Action EUROFANCOLENparticipant5.380.17011
2012-12-01Gene Therapy for X-linked Chronic Granulomatous Disease (CGD) NET4CGDcoordinator5.999.60711
2011-12-01Gene Therapy for Inherited Skin Adhesion Disorders GT-SKINparticipant2.210.0001
2011-03-01Phase I/II ex vivo gene therapy clinical trial for recessive dystrophic epidermolysis bullosa using skin equivalent grafts genetically corrected with a COL7A1-encoding SIN retroviral vector GENEGRAFTparticipant4.961.65410
2009-01-01Persisting Transgenesis PERSISTparticipant11.181.41129
2008-10-01Development of targeted DNA-chips for high throughput diagnosis of neuromuscular disorders NMD-CHIPparticipant2.907.73514
2007-01-01Baculovirus vectors for gene therapy BACULOGENESparticipant2.499.7469
2007-01-01Translational research in Europe - Assessment and treatment of neuromuscular diseases TREAT-NMDparticipant10.000.00027
2006-12-01Amplification of human myogenic stem cells in clinical conditions MYOAMPparticipant2.480.00010
2006-04-01European network for the advancement of clinical gene transfer and therapy CLINIGENEparticipant12.000.00043
2006-01-01Molecular imaging in tissue and cells by computer-assisted innovative multimode mass spectrometry COMPUTISparticipant2.200.0007
2005-07-01Ex vivo gene therapy for recessive dystrophic epidermlysis bullosa: pre-clinical and clinical studies THERAPEUSKINparticipant284.0009
2004-11-01Concerted Safety & Efficiency Evaluation of Retroviral Transgenesis in Gene Therapy of Inherited Diseases CONSERTparticipant11.635.00024

Alias institution names:
  • ASSOCIATION GENETHON
  • GENETHON

Data provision: © European Union; Source: CORDIS, http://cordis.europa.eu/ | This page is not provided by the European Commission see:Impressum